Abstract
Jordan' s pharmaceutical market environment has been subject to criticism in
the past, in particular from multinationals. This report is ideal for
executives wanting to understand the key drivers in the pharmaceutical market
and have access to a wealth of statistical data, including five-year market
projections. Included with the report are 3 free quarterly updated outlook
reports, enabling you to keep up to date with market developments for a year.
Includes 3 quarterly updated outlook reports!
Jordan is a small but strategically located country in the Middle East,
bordering Israel, Syria, Iraq and Saudi Arabia. Although it lacks the oil
reserves of many of its neighbours and is relatively poor in comparison, it
boasts good links with the West and is a key player on the local political
scene.
Both the government and private sector are committed to upgrading and
modernising Jordan' s healthcare provision. The country has a reputation in the
region for its high standards of services provided and both public and private
hospitals have been expanding and upgrading in recent years.
Since its accession to the WTO, Jordan has demonstrated its commitment to WTO
rules, in particular the TRIPS agreement, for example by recent improvements
to, and enforcement of, IP protection. However, Jordan' s regulatory
environment is still being criticised, mainly by international manufacturers,
who accuse Jordan of regulatory discrimination in favour of domestic producers.
Jordan has a relatively strong level of domestic production; however, the
majority is exported, resulting in a market still dependent on imports. In
2005, Jordan imported pharmaceuticals valued at US$249.0 million, more than
80% of which was composed of retail medicaments. The EU and Switzerland were
the leading suppliers in 2005, accounting for 75.4% of the market. Exports
totalled US$286.8 million in 2005, primarily semi-finished and retail
medicaments destined for other countries in the MENA region.
View Cart
